Protalix BioTherapeutics (PLX) EBT Margin (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly EBT Margin of 62.64% for Q1 2026, up 9954.0% year-over-year from N/an in Q1 2025, and up 252.5% quarter-over-quarter from 41.08% in Q4 2025.
Protalix BioTherapeutics (PLX) EBT Margin (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 62.64% for Q1 2026.
- In Q1 2026, EBT Margin rose 9954.0% year-over-year to 62.64%; the TTM figure through Mar 2026 stood at 26.57% (up 1033.0% YoY), while the FY2025 annual figure was 8.68%, down 2498.0% from the prior year.
- EBT Margin for Q1 2026 stood at 62.64%, up from 41.08% in the prior quarter.
- The five-year high for EBT Margin was 65.12% in Q4 2024, with the low at 210.31% in Q4 2023.
- The 5-year median for EBT Margin is 16.86% (2024), against an average of 23.19%.
- The sharpest annual moves came in 2023 and 2024: EBT Margin sank 17306 bps in 2023, then jumped 27543 bps in 2024.
- Protalix BioTherapeutics' EBT Margin stood at 37.25% in 2022, then tumbled by 465 bps to 210.31% in 2023, then jumped by 131 bps to 65.12% in 2024, then plunged by 163 bps to 41.08% in 2025, then soared by 252 bps to 62.64% in 2026.
- Business Quant data shows PLX's EBT Margin at 62.64% in Q1 2026, 41.08% in Q4 2025, and 12.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Protalix BioTherapeutics | 188.37 Mn | 147.71 Mn | 12.13 Mn | 24.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.43% |
| Mar 31, 2026 | 62.64% |
| Dec 31, 2025 | -41.08% |
| Sep 30, 2025 | 12.54% |
| Jun 30, 2025 | 4.22% |
| Mar 31, 2025 | -36.90% |
| Dec 31, 2024 | 65.12% |
| Sep 30, 2024 | 21.40% |
| Jun 30, 2024 | -16.86% |
| Mar 31, 2024 | -126.28% |
| Dec 31, 2023 | -210.31% |
| Sep 30, 2023 | -16.62% |
| Jun 30, 2023 | 56.01% |
| Mar 31, 2023 | -30.62% |
| Dec 31, 2022 | -37.25% |
| Sep 30, 2022 | -25.15% |
| Jun 30, 2022 | -60.94% |
| Mar 31, 2022 | -14.21% |
| Dec 31, 2021 | -77.37% |
| Sep 30, 2021 | -35.63% |